ES2356308T3 - Uso de derivados peptídicos para inducir la diferenciación celular. - Google Patents
Uso de derivados peptídicos para inducir la diferenciación celular. Download PDFInfo
- Publication number
- ES2356308T3 ES2356308T3 ES03743087T ES03743087T ES2356308T3 ES 2356308 T3 ES2356308 T3 ES 2356308T3 ES 03743087 T ES03743087 T ES 03743087T ES 03743087 T ES03743087 T ES 03743087T ES 2356308 T3 ES2356308 T3 ES 2356308T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- dicarbamine
- baselineskip
- cells
- chemotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 44
- 230000024245 cell differentiation Effects 0.000 title abstract description 16
- 201000001441 melanoma Diseases 0.000 claims abstract description 53
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 7
- 125000003368 amide group Chemical group 0.000 claims abstract description 3
- 125000003277 amino group Chemical group 0.000 claims abstract description 3
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 3
- 238000002512 chemotherapy Methods 0.000 claims description 80
- 206010028980 Neoplasm Diseases 0.000 claims description 71
- 238000002560 therapeutic procedure Methods 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 23
- 208000004235 neutropenia Diseases 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- 238000009169 immunotherapy Methods 0.000 claims description 12
- 229940079322 interferon Drugs 0.000 claims description 11
- 230000009467 reduction Effects 0.000 claims description 9
- 239000004215 Carbon black (E152) Substances 0.000 claims description 8
- 102000014150 Interferons Human genes 0.000 claims description 8
- 108010050904 Interferons Proteins 0.000 claims description 8
- 229930195733 hydrocarbon Natural products 0.000 claims description 8
- 206010043554 thrombocytopenia Diseases 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 3
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 99
- 230000000694 effects Effects 0.000 abstract description 60
- 210000004881 tumor cell Anatomy 0.000 abstract description 23
- 239000000824 cytostatic agent Substances 0.000 abstract description 12
- 230000001085 cytostatic effect Effects 0.000 abstract description 10
- 210000002780 melanosome Anatomy 0.000 abstract description 8
- 239000000411 inducer Substances 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 230000010534 mechanism of action Effects 0.000 abstract description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 4
- 125000004442 acylamino group Chemical group 0.000 abstract 3
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- KZIMLUFVKJLCCH-UHFFFAOYSA-N 5-[2-(1h-imidazol-5-yl)ethylamino]-5-oxopentanoic acid Chemical compound OC(=O)CCCC(=O)NCCC1=CNC=N1 KZIMLUFVKJLCCH-UHFFFAOYSA-N 0.000 abstract 1
- 241000699660 Mus musculus Species 0.000 abstract 1
- -1 cyclic imide Chemical class 0.000 abstract 1
- 238000003304 gavage Methods 0.000 abstract 1
- 238000011580 nude mouse model Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 42
- 230000004069 differentiation Effects 0.000 description 39
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 29
- 229960004397 cyclophosphamide Drugs 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 28
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 27
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 24
- 229960004562 carboplatin Drugs 0.000 description 24
- 238000012360 testing method Methods 0.000 description 23
- 210000001185 bone marrow Anatomy 0.000 description 19
- 230000012010 growth Effects 0.000 description 19
- 210000000805 cytoplasm Anatomy 0.000 description 18
- 230000006907 apoptotic process Effects 0.000 description 17
- 108010047761 Interferon-alpha Proteins 0.000 description 15
- 102000006992 Interferon-alpha Human genes 0.000 description 15
- 210000004698 lymphocyte Anatomy 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 239000008187 granular material Substances 0.000 description 13
- 210000005259 peripheral blood Anatomy 0.000 description 13
- 239000011886 peripheral blood Substances 0.000 description 13
- 231100000226 haematotoxicity Toxicity 0.000 description 12
- 210000004940 nucleus Anatomy 0.000 description 12
- 230000004614 tumor growth Effects 0.000 description 12
- 230000007423 decrease Effects 0.000 description 11
- 238000001493 electron microscopy Methods 0.000 description 11
- 210000000265 leukocyte Anatomy 0.000 description 11
- 108010078049 Interferon alpha-2 Proteins 0.000 description 10
- 206010028851 Necrosis Diseases 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 230000017074 necrotic cell death Effects 0.000 description 10
- 238000009534 blood test Methods 0.000 description 9
- 231100000433 cytotoxic Toxicity 0.000 description 9
- 230000001472 cytotoxic effect Effects 0.000 description 9
- 210000003714 granulocyte Anatomy 0.000 description 9
- 230000035508 accumulation Effects 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 206010049466 Erythroblastosis Diseases 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 238000001574 biopsy Methods 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 230000002489 hematologic effect Effects 0.000 description 7
- 201000002364 leukopenia Diseases 0.000 description 7
- 230000011278 mitosis Effects 0.000 description 7
- 108010077544 Chromatin Proteins 0.000 description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 210000003483 chromatin Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 231100001022 leukopenia Toxicity 0.000 description 5
- 210000003887 myelocyte Anatomy 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 210000003705 ribosome Anatomy 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
- 108010034791 Heterochromatin Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 230000002012 hematotoxic effect Effects 0.000 description 4
- 210000004458 heterochromatin Anatomy 0.000 description 4
- 210000003924 normoblast Anatomy 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 210000004765 promyelocyte Anatomy 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- 206010061188 Haematotoxicity Diseases 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000925 erythroid effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000000224 granular leucocyte Anatomy 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 238000010562 histological examination Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000000394 mitotic effect Effects 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 230000003039 myelosuppressive effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000000399 optical microscopy Methods 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BADMGRJDJPQBLS-UNTFVMJOSA-N 1-methyl-1-nitroso-3-[(2r,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]urea Chemical compound O=NN(C)C(=O)N[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O BADMGRJDJPQBLS-UNTFVMJOSA-N 0.000 description 2
- SYEWHONLFGZGLK-UHFFFAOYSA-N 2-[1,3-bis(oxiran-2-ylmethoxy)propan-2-yloxymethyl]oxirane Chemical compound C1OC1COCC(OCC1OC1)COCC1CO1 SYEWHONLFGZGLK-UHFFFAOYSA-N 0.000 description 2
- 108010087806 Carnosine Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 2
- 231100000605 Toxicity Class Toxicity 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 2
- 239000012568 clinical material Substances 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002895 hyperchromatic effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000065 noncytotoxic Toxicity 0.000 description 2
- 230000002020 noncytotoxic effect Effects 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WAAZXLNQUDXDRP-VIFPVBQESA-N (3S)-3-acetamido-4-[2-(1H-imidazol-5-yl)ethylamino]-4-oxobutanoic acid Chemical compound CC(=O)N[C@@H](CC(O)=O)C(=O)NCCC1=CNC=N1 WAAZXLNQUDXDRP-VIFPVBQESA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- CCLQKVKJOGVQLU-QMMMGPOBSA-N L-homocarnosine Chemical compound NCCCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 CCLQKVKJOGVQLU-QMMMGPOBSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical class OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 231100000042 hematotoxic Toxicity 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 108700002498 homocarnosine Proteins 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011368 intensive chemotherapy Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000010644 positive regulation of cell differentiation Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 125000005289 uranyl group Chemical group 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2002105392/14A RU2217196C2 (ru) | 2002-02-28 | 2002-02-28 | Способ индукции дифференцировки клеток |
| RU2002105392 | 2002-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2356308T3 true ES2356308T3 (es) | 2011-04-06 |
Family
ID=27764932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03743087T Expired - Lifetime ES2356308T3 (es) | 2002-02-28 | 2003-02-28 | Uso de derivados peptídicos para inducir la diferenciación celular. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7759313B2 (OSRAM) |
| EP (1) | EP1491206B9 (OSRAM) |
| JP (1) | JP4711626B2 (OSRAM) |
| CN (1) | CN1649612B (OSRAM) |
| AT (1) | ATE488234T1 (OSRAM) |
| AU (1) | AU2003235538A1 (OSRAM) |
| CY (1) | CY1111265T1 (OSRAM) |
| DE (1) | DE60334978D1 (OSRAM) |
| DK (1) | DK1491206T3 (OSRAM) |
| EA (1) | EA007474B1 (OSRAM) |
| ES (1) | ES2356308T3 (OSRAM) |
| HK (1) | HK1079990B (OSRAM) |
| IL (3) | IL163763A0 (OSRAM) |
| PT (1) | PT1491206E (OSRAM) |
| RU (1) | RU2217196C2 (OSRAM) |
| SI (1) | SI1491206T1 (OSRAM) |
| UA (1) | UA85039C2 (OSRAM) |
| WO (1) | WO2003072124A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MC200060A1 (fr) * | 2002-10-04 | 2003-05-28 | M Exsymol Sa | Produit de couplage entre la tryptamine et un alpha-aminoacide son procédé de préparation et son application dans le domaine de la neuro-cosmétique |
| RU2335495C2 (ru) * | 2005-06-15 | 2008-10-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | N-ацильные производные аминокислот, их фармацевтически приемлевые соли, фармацевтическая композиция и применение в качестве гиполипидемических средств |
| RU2378284C2 (ru) * | 2008-02-13 | 2010-01-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Способы получения n-ацильных производных аминокислот (варианты) |
| RU2406727C2 (ru) * | 2008-02-13 | 2010-12-20 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств |
| RU2359030C1 (ru) * | 2008-03-19 | 2009-06-20 | Общество С Ограниченной Ответственностью "Лаборатория Клеточных Технологий" | Способ получения эндотелиальных клеток из эмбриональных стволовых клеток человека (варианты) |
| RU2373934C1 (ru) | 2008-03-19 | 2009-11-27 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств |
| JP5370957B2 (ja) * | 2008-08-20 | 2013-12-18 | 学校法人日本大学 | アポトーシス抑制剤 |
| CN104257515B (zh) * | 2010-10-22 | 2017-05-03 | 新钰生技股份有限公司 | 具有抑制黑色素生成的甘胺酸衍生物及使用其的美白组成物 |
| US20130195782A1 (en) * | 2010-10-22 | 2013-08-01 | Corum Inc. | Novel Glycine Derivative Capable Of Inhibiting Melanin Formation And Composition Using The Same |
| UA115431C2 (uk) * | 2011-10-11 | 2017-11-10 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Застосування глутарилгістаміну для лікування захворювань дихальних шляхів |
| CN103382179A (zh) * | 2013-06-05 | 2013-11-06 | 四川百利药业有限责任公司 | 英加韦林的多晶型物及其制备方法 |
| RU2628800C2 (ru) * | 2014-03-12 | 2017-08-22 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами |
| JP7531918B2 (ja) * | 2018-09-25 | 2024-08-13 | ミエロ セラピューティクス ゲーエムベーハー | 致死的な放射線への曝露に関連する症状の治療における使用のためのイミダゾリルエタンアミドペンタン二酸 |
| RU2726119C1 (ru) * | 2019-11-22 | 2020-07-09 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Новые производные полиолов, их применение, фармацевтическая композиция на их основе |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6016934A (ja) | 1983-07-06 | 1985-01-28 | Kaneshiro Nagai | 抗腫瘍剤 |
| JPS6016926A (ja) * | 1983-07-06 | 1985-01-28 | Kaneshiro Nagai | 抗腫瘍剤 |
| US4816442A (en) * | 1986-11-07 | 1989-03-28 | Collagen Corporation | Method of inhibiting tumor growth sensitive to CIF-βtreatment |
| JPS6442430A (en) | 1987-08-11 | 1989-02-14 | Nippon Univ | Side effect remover for chemotherapeutic agent |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| JPH0585942A (ja) | 1991-02-26 | 1993-04-06 | Denki Kagaku Kogyo Kk | インターフエロン−ヒアルロン酸及び／又はその塩の結合体 |
| MY128261A (en) * | 1992-10-27 | 2007-01-31 | Merck Sharp & Dohme | New substituted azetidinones as anti-inflammatory and antidegenerative agents |
| GB9308695D0 (en) * | 1993-04-27 | 1993-06-09 | Celltech Ltd | Peptidyl derivatives |
| IL110296A (en) * | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
| WO1995011699A1 (en) | 1993-10-29 | 1995-05-04 | The Trustees Of Boston University | Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents |
| JP3517274B2 (ja) | 1994-05-20 | 2004-04-12 | 株式会社ナリス化粧品 | 皮膚組成物 |
| RU2120298C1 (ru) * | 1995-11-28 | 1998-10-20 | Товарищество с ограниченной ответственностью "Верта" | Иммуностимулятор и препарат на его основе |
| FR2762315B1 (fr) * | 1997-04-22 | 1999-05-28 | Logeais Labor Jacques | Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha |
| RU2141483C1 (ru) | 1997-07-04 | 1999-11-20 | Небольсин Владимир Евгеньевич | Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция |
| EP1028745B1 (en) | 1997-11-07 | 2009-01-07 | Mayo Foundation For Medical Education And Research | Low-dose interferon immunotherapy |
| US6838436B1 (en) * | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
| AU768269B2 (en) | 1998-10-02 | 2003-12-04 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Apoptosis inducing agents and methods |
-
2002
- 2002-02-28 RU RU2002105392/14A patent/RU2217196C2/ru not_active IP Right Cessation
-
2003
- 2003-02-28 AU AU2003235538A patent/AU2003235538A1/en not_active Abandoned
- 2003-02-28 HK HK06100072.5A patent/HK1079990B/zh not_active IP Right Cessation
- 2003-02-28 DE DE60334978T patent/DE60334978D1/de not_active Expired - Lifetime
- 2003-02-28 WO PCT/RU2003/000072 patent/WO2003072124A1/ru not_active Ceased
- 2003-02-28 IL IL16376303A patent/IL163763A0/xx unknown
- 2003-02-28 EA EA200401105A patent/EA007474B1/ru unknown
- 2003-02-28 CN CN038094959A patent/CN1649612B/zh not_active Expired - Lifetime
- 2003-02-28 US US10/505,976 patent/US7759313B2/en not_active Expired - Lifetime
- 2003-02-28 AT AT03743087T patent/ATE488234T1/de active
- 2003-02-28 PT PT03743087T patent/PT1491206E/pt unknown
- 2003-02-28 UA UA20040907835A patent/UA85039C2/uk unknown
- 2003-02-28 ES ES03743087T patent/ES2356308T3/es not_active Expired - Lifetime
- 2003-02-28 SI SI200331938T patent/SI1491206T1/sl unknown
- 2003-02-28 DK DK03743087.3T patent/DK1491206T3/da active
- 2003-02-28 JP JP2003570868A patent/JP4711626B2/ja not_active Expired - Lifetime
- 2003-02-28 EP EP03743087A patent/EP1491206B9/en not_active Expired - Lifetime
-
2004
- 2004-08-26 IL IL163763A patent/IL163763A/en active IP Right Grant
-
2010
- 2010-11-30 IL IL209653A patent/IL209653A0/en unknown
-
2011
- 2011-02-09 CY CY20111100154T patent/CY1111265T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005532269A (ja) | 2005-10-27 |
| CN1649612B (zh) | 2011-04-06 |
| EP1491206B9 (en) | 2011-03-09 |
| RU2217196C2 (ru) | 2003-11-27 |
| UA85039C2 (uk) | 2008-12-25 |
| IL163763A (en) | 2011-12-29 |
| ATE488234T1 (de) | 2010-12-15 |
| US20050180953A1 (en) | 2005-08-18 |
| CN1649612A (zh) | 2005-08-03 |
| HK1079990B (zh) | 2011-12-09 |
| SI1491206T1 (sl) | 2011-03-31 |
| US7759313B2 (en) | 2010-07-20 |
| CY1111265T1 (el) | 2015-08-05 |
| EA200401105A1 (ru) | 2004-12-30 |
| IL209653A0 (en) | 2011-02-28 |
| WO2003072124A1 (en) | 2003-09-04 |
| IL163763A0 (en) | 2005-12-18 |
| EA007474B1 (ru) | 2006-10-27 |
| PT1491206E (pt) | 2011-02-11 |
| EP1491206B1 (en) | 2010-11-17 |
| DK1491206T3 (da) | 2011-03-14 |
| EP1491206A4 (en) | 2006-01-11 |
| HK1079990A1 (en) | 2006-04-21 |
| JP4711626B2 (ja) | 2011-06-29 |
| EP1491206A1 (en) | 2004-12-29 |
| DE60334978D1 (de) | 2010-12-30 |
| AU2003235538A1 (en) | 2003-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2356308T3 (es) | Uso de derivados peptídicos para inducir la diferenciación celular. | |
| US6610699B2 (en) | Use of L-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity | |
| Tampellini et al. | Docetaxel chronopharmacology in mice | |
| ES2702128T3 (es) | Antagonista o agonista inverso de RAR para uso en el tratamiento de efectos secundarios de quimioterapia y/o terapia de radiación | |
| JP4057648B2 (ja) | 造血前駆細胞の増殖を促進するチオール類 | |
| US5955432A (en) | Metabolic effects of certain glutathione analogs | |
| EP2059254B1 (en) | Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists | |
| RU2730998C2 (ru) | Композиции форболовых эфиров и способы их применения для лечения или уменьшения продолжительности цитопении | |
| Chen et al. | Carrageenan-ferrocene-eicosapentaenoic acid composite hydrogel induce ferroptosis and apoptosis for anti-tumor recurrence and metastasis | |
| Poydock et al. | Inhibiting effect of vitamins C and B12 on the mitotic activity of ascites tumors | |
| US20090232906A1 (en) | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions | |
| WO2020217472A1 (ja) | 治療抵抗性がんの予防又は治療用の医薬組成物 | |
| Li et al. | Inhibition of growth of human nasopharyngeal cancer xenografts in SCID mice by arsenic trioxide | |
| CA2717181A1 (en) | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions | |
| CA2211445A1 (en) | Novel medical use of heme products | |
| KR102694803B1 (ko) | A-노르-5α안드로스테인 화합물계 약물 및 항암제의 병용 | |
| RU2317074C1 (ru) | Ингибитор дифференцировки кроветворных клеток-предшественников | |
| CN109985030B (zh) | 醌式查尔酮化合物在制备抗肿瘤药物中的应用 | |
| Teicher et al. | Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma | |
| CN115137831B (zh) | 虾青素在制备抗血管生成药物增效剂中的应用以及一种药物组合物 | |
| US20110124741A1 (en) | Radiosensitizer compositions comprising schisandra chinensis(turcz.)baill and methods for use | |
| JP3816522B2 (ja) | 造血機能に関して刺激活性を示すｍｄｐ誘導体および複合体ならびにそれらを含む組成物 | |
| RU2782931C2 (ru) | Производные индол-3-карбоновой кислоты, обладающие противоопухолевой активностью | |
| US20110256236A1 (en) | Enhancement of the Anti-Leukemic Effect of Thalidomide | |
| TWI722492B (zh) | 含蓮蓬萃取物之組合物及其用於治療頭頸癌症之用途 |